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tions to improve limited HL. METHODS: Systematic review
with electronic database searches (MEDLINE, EMBASE,
PsycINFO, CINHAL and COCHRANE-Library; from 1980
through January 2008), screening of selected books and reference
lists, and expert contacts. We included observational and inter-
ventional studies that reported HL of participants as one
outcome measure. We included populations at high risk for low
HL as well as patients with 1) diabetes mellitus, or 2) hyperlipi-
demia. Studies were screened for eligibility, unclear cases were
discussed in a consensus meeting. We performed data extraction
and quality assessment; results were checked by a second
reviewer. RESULTS: We retrieved 2340 papers and included 10
studies for the ﬁnal analysis. On the health care system level, the
additional spending due to low HL corresponds to 3% to 5% of
the total health care costs (3 studies with data of more than
50,000 persons from U.S. and Swiss settings). The prevalence of
limited HL is considerable (range: 34% to 59%; 4 studies;
110,000 nationally representative persons). Three U.S. studies
(data of 3600 persons) report the additional costs of limited HL
on the patient level (additional expenditures per year per person
with limited HL compared to a reference group with adequate
HL; range: US $143 to 7798). One systematic review reported
cost-effectiveness data of patient self management programs for
diabetes and showed inconclusive results. CONCLUSIONS: The
costs of limited HL for the health care system may be substantial,
but few studies were retrieved, and the results are heterogeneous.
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OBJECTIVES: To analyze the costs and discharge status for
patients with prolonged mechanical ventilation undergoing tra-
cheostomy (DRG code 483) in Spain and to examine the impact of
age in terms of hospital outcome. METHODS: From the
2004 National Hospital Discharge Database records for all
patients aged >16 years undergoing mechanical ventilation were
retrieved. Demographic characteristics, clinical outcomes and
hospital-resources utilization were examined. An exploratory
logistic regression analysis and a multiple linear regression analy-
sis were performed to identify factors associated with in-hospital
mortality and LOS respectively. To depict the amount of resources
spent to procure a given level of desired outcome (hospital sur-
vival) we also determined the cost per survivor based in the
average National Health Service Charges for DRG 483
(€49,365.37).RESULTS: From a total of 33,416 cases undergoing
mechanical ventilation during 2004, 4,277 cases (13%) with a
ﬁnal DRG code of 483 were selected and eligible for analysis.
Median age was 65 yr (p25:50; p75:73); 67%were men and 54%
surgical patients. According to Charlson index, 56% of cases had
no associated comorbidity. Overall in-hospital mortality was
41%. Total costs of hospitalizations exceeded € 211 million. An
inverse relationship between survival rate and age was consis-
tently observed after adjusting by other clinical variables, and this
resulted in an age-related increased cost per survivor (€58,588 in
patients aged <45 yrs; €75,1531 in those aged 45–64 yrs; 99,720
in 65–74 yrs and €12,5903 in those older than 74 yrs).CONCLU-
SIONS: Patients who require tracheostomy for prolonged
mechanical ventilation have high resource utilization and rela-
tively poor outcomes. Age has a signiﬁcant impact on outcomes in
patients under DRG 483 both from clinical and economic per-
spectives. These analyses will help inform health care decision-
making and resource planning in the face of an ageing population.
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OBJECTIVES: In the Hungarian DRG system it can frequently
occur that real costs exceed the amount of reimbursements. Our
goal was to compare the difference between the real clinical cost
and the normative DRG reimbursement in a single patient case.
METHODS: Data derive from the ﬁnancial database of the
National Health Insurance Fund Administration (NHIFA) and
the clinical database of the University of Pecs. We made an outlay
of the patient’s variable costs for drugs, infusions, nutritive prod-
ucts, transfusions, laboratory diagnostics and imagining proce-
dures used. The results we obtained were compared to standards
calculated by the NHIFA for the surgical treatment of oesoph-
ageal cancer. The case was grouped to DRG code number 9540
which had 13.2 weight-number. RESULTS: The weight-number
of medication components in this DRG category was 1.68
(12.7% of the total 13.2 weight-number). The real medication
cost was HUF 3,960,000 which represented 39.6 weight-number.
This exceeded the DRG medication reimbursement 23.6 times
and was 3 times more than the total reimbursement. In this way
just the medication cost was 300% of the total DRG ﬁnancing.
The excess cost was generated by increased drug usage due to
the patient’s severe septic complications. The main elements of
medications were a four-day activated protenine-C treatment
representing 53.5% of total drug expenditure, IgM enriched
polyclonal antibody therapy (28.4%) and 5 different antibiotics
(7.24%). The treatment of severe sepsis made up 89.1% of total
medication cost. As an excess, 27.6 weight-number was reim-
bursed topping the 13.2 weight-number for the original DRG.
CONCLUSIONS: There was a signiﬁcant gap between real hos-
pital costs and health insurance reimbursement. On the basis of
this analysis, the NHIFA found our demand for extra ﬁnance
justiﬁed and reimbursed our institution with the extra cost
applied for. Our case signiﬁcantly contributed to regulation
changes dealing with extra ﬁnancing for outlayer patient’s costs
in the DRG system.
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OBJECTIVES: German hospital reimbursement changed signiﬁ-
cantly as a result of the introduction of Diagnosis Related
Groups (DRG) in the year 2004. Based on this development no
current data on the direct costs of adverse drug reactions (ADR)
leading to hospital admissions in departments of internal
medicine is available. The objective of our project is to quantify
the ADR-related economic burden of the respective ADRs in
Germany. METHODS: A total of 1242 patient records of ADRs
leading to internal medicine hospitalization were surveyed in 4
regional pharmacovigilance centres in Germany within the years
A364 Abstracts
2006 and 2007. The WHO-Adverse Reaction Terminology
record entries were re-coded in International Classiﬁcation of
Diseases (ICD-10-GM Version 2008) format and afterwards
assigned to the matching DRG (G-DRG 2008) including supple-
mentary and additional fees. RESULTS: Incidence of internal
hospitalization was estimated to approximately 3.25%. Mean
age of patients was 71.3 years (SD 14.5). Average inpatient
length of stay in the group was 9.3 days (SD 7.0) and is therefore
2.3 days higher than average length of stay in German internal
wards (7.0 days in the year 2006). Most frequent ADRs are
gastrointestinal bleeding (n = 205), hypoglycemia (n = 201), and
bradycardia (n = 61). Average treatment costs of a single ADR
were estimated to be approximately €2044 based on a state-wide
base-rate of €2800. CONCLUSIONS: Before the introduction of
the DRG system, direct medical costs of ADR-treatment in
Germany were €400 million in the year 2002 (Schneeweiss et al.,
Eur J Clin Pharmacol 2002;58:285–91. This equals—given an
ADR-incidence of 2.1%—case-related costs of €3,700 per
person. Our results provide an informative basis, that this former
person-related amount seems to be too high against the back-
ground of DRG introduction. Considering the apparently higher
incidence rate of 3.25%, the present total costs are approxi-
mately the same.
HEALTH CARE USE & POLICY STUDIES—
Drug/Device/Diagnostic Use & Policy
PHP9
DELAY OF DECISION-MAKING ON PHARMACEUTICAL
REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY
Nagy Z1, Molnár MP2, Sebestyen A3, Kriszbacher I4,Vas G4, Boncz I4
1Health Insurance Supervisory Authority, Budapest, Hungary, 2National
Health Insurance Fund Administration (OEP), Budapest, Hungary,
3National Health Insurance Fund Administration, Pecs, Hungary,
4University of Pecs, Pecs, Hungary
OBJECTIVES: On the May 1, 2004 Hungary—together with
many European countries—joined the European Union which
resulted in several changes in the Hungarian legislation. In the
coverage policy of pharmaceuticals, the Directive 89/105/EEC of
the Council of the European Communities on Transparency was
implemented in Hungary, in order to provide regulation on deci-
sion on drug prices. The aim of our study is to calculate the
average delay of decision-making on pharmaceutical reimburse-
ment. METHODS: The data derive from the drug reimburse-
ment database of the National Health Insurance Fund
Administration (OEP) of Hungary covering the 3 year period of
2005–2007. We calculated the delay as the time between the
submission of application by the manufacturer and the ﬁrst day
of reimbursement of drug. Our analysis covered drugs submitted
within the frame of normal procedure, drugs submitted in the
simpliﬁed procedure were omitted. RESULTS: Between 2005–
2007, the total number of applications was 172, 161, 140; while
the average delay was 217, 255, 166 days respectively. Most of
the application represented new (innovative) drugs (70, 75, 65
pieces) or new indications of drugs already reimbursed in other
indication (27, 28, 27 pieces). Between 2005–2007 the average
delay for new (innovative) drugs was 258, 222, 166 days, while
for new indications it was 194, 319, 203 days respectively. CON-
CLUSIONS: The introduction of EU transparency directive
provided a strong regulatory framework for decision-making
process on drug reimbursement. In the normal procedure we
found signiﬁcant differences in time delay of decision according
to submission categories. However, in 2007 the average delay
signiﬁcantly decreased compared to previous years.
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OBJECTIVES: In 2006, pharmaceuticals were sold in Finland
approximately €2.4 billion (a 1.6% reduction from 2005).
However, pharmacy and hospital markets may have performed
in different ways. The objective is to develop descriptive
performance indicators for pharmaceutical market dynamics in
Finland. METHODS: Total numbers of marketers (M), active
substances (S), trade names (T) and packages (P) (1995–2007)
were extracted from the market database SLD Pharma (Finnish
Pharmaceutical Data Ltd.). We restricted data only to numbers
that were associated with a marketing authorisation and positive
annual wholesale ﬁgures. Total number and indicator (S/M, T/M,
P/M, T/S, P/T, P/S) analyses were segmented by markets (phar-
macy, hospital) and calendar year. We compared ﬁgures in 2007
to base year 1995. RESULTS: In 2007 pharmacy market, the
total number of marketers was 38% (26% in hospital market),
active substances 15% (18%), trade names 44% (28%), and
packages 26% (12%) higher than in 1995. Compared to 1995,
the pharmacy market S/M indicator in 2007 was 0.83 (0.93 in
hospital market), whereas T/M was 1.04 (1.02), P/M was 0.91
(0.89), T/S was 1.25 (1.09), P/T was 0.88 (0.87), and P/S was
1.10 (0.95). CONCLUSIONS: In Finland 1995–2007 numbers
of marketers, trade names (products) and sales packages in-
creased more in the pharmacy market. Pharmacy market indica-
tors (S/M -17%, T/S +25%, P/S +10%) suggest an increase in
competition, and may partly be explained by generic substitution
that was introduced in Finland on 1 April 2003.
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